EQS-News: Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.

1st Quarter 2024:

• Sales of € 67.6 million (previous year: € 57.9 million)
• EBIT before special items of € 15.0 million (previous year: € 10.6 million)
• Net income € 8.5 million (previous year: € 4.7 million) 

Forecast FY 2024:

• Sales of just under € 265 Mio. (confirmed)
• EBIT before special items of around € 50 million (confirmed)

Berlin, 14 May 2024. Die Eckert Ziegler SE (ISIN DE0005659700, TecDAX) increased sales by 17% to € 67.6 million in the first quarter of 2024 compared to the same period of the previous year. EBIT before special items from continuing operations (adjusted EBIT) rose by around € 4.4 million to € 15.0 million. Net profit (from continuing and discontinued operations) increased by 79% and reached € 8.5 million or € 0.41 per share.

In the first three months of the year, sales in the Medical segment were around € 10.4 million or 43% higher than in the previous year at € 34.6 million. The main growth driver continues to be the business with pharmaceutical radioisotopes, while sales from plant engineering also increased significantly.
The Isotope Products segment generated external sales of € 33.1 million, which was € 0.7 million or around 2% lower than in the first three months of 2023. Compared to the same period of the previous year, there were shifts between the product groups towards higher-margin products.

The forecast for the 2024 financial year published on March 22, 2024, remains unchanged. The Executive Board continues to expect sales of just under € 265 million and EBIT (earnings before interest and taxes) from continuing operations before special items of around € 50 million.

The complete quarterly report can be viewed here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz124e.pdf

About Eckert Ziegler.
Eckert Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com